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lood Pressure
nd the Therapy of
dvanced Heart Failure*
ay N. Cohn, MD
inneapolis, Minnesota
n the 1960s, when we initially introduced the concept of
asodilator therapy for the failing heart (1), we had to
vercome skepticism about the safety and efficacy of this
pproach. Health care workers were focused on ausculatory
lood pressure (BP), which often was falsely reduced in sick
atients (2), and vasoconstrictor drugs frequently were
dministered to restore perceived low pressure, which was
hought to be harmful. The idea that vasodilator drugs,
hich are designed to lower pressure, would be safe in such
n individual was anathema.
See page 1423
Our early experience convinced us of the wisdom of this
pproach even when the directly measured arterial pressure
as low. One of our first patients was in severe pump failure
fter an acute myocardial infarction. Our bedside hemody-
amic assessment (3) revealed a brachial arterial pressure of
0/70 mm Hg and a cardiac output of 2.3 l/min. Having
lready demonstrated the favorable effects of sodium nitro-
russide on cardiac output in such patients (4), we initiated
n infusion which, as expected, doubled cardiac output and
roduced dramatic clinical improvement while reducing
rterial pressure to 84/60 mm Hg. Because we were satisfied
ith our titration and it was now 2 AM, I left orders with the
ursing staff to maintain systolic pressure 90 mm Hg by
djusting the dose of nitroprusside. When I returned at
AM, the nurse informed me apologetically that she had
ailed in her effort. Despite initiating a second intravenous
ite for nitroprusside and even pumping the infusion to
aintain a high flow rate, she was unable to keep the
ystolic pressure below 90 mm Hg. The patient’s cardiac
utput had increased to 7 l/min. The lesson was clear:
asodilator drugs given to a patient with severe heart failure
HF) in whom impedance is limiting cardiac output may
esult in a sustained rise in pressure. Pressure is not the
arget; flow should be the target!
Despite the clarity of this physiologic principle, clinicians
till often focus on BP in their management of sick patients,
erhaps because it is easy to measure and generates a
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiovascular Division, Department of Medicine, University of Min-esota Medical School, Minneapolis, Minnesota.umber that people think they understand. And because of
hat number, patients may be deprived of effective therapy,
uch as angiotensin-converting enzyme inhibitors and beta-
lockers. Indeed, nurses often withhold these drugs, even
hen they are prescribed, if the BP is low in a hospitalized
atient. Hypotension can of course be a concern when it is
ssociated with cerebral, cardiac, or renal evidence of inad-
quate perfusion. But in the absence of such signs or
ymptoms, the therapeutic goal is to maintain treatment
ith drugs that lower impedance, improve flow, and slow
eft ventricular (LV) structural remodeling.
Systolic BP is a product of the stroke volume and the
mpedance to ejection. When the heart is healthy, imped-
nce does not affect stroke volume but rather determines
ressure. In the failing heart, however, impedance controls
troke volume (5). The neurohormonal and vascular conse-
uences of HF (6) raise impedance, and stroke volume then
ecomes a measure of the severity of LV dysfunction. Under
hese circumstances, hypotension is a consequence of re-
uced contractile function of the heart. The hypotensive
atient with HF, therefore, should be at high risk because of
he severity of HF and should be a candidate for the most
ggressive therapy to lower impedance and slow the pro-
ression of structural and functional disease.
The study by Rouleau et al. (7) in this issue of the Journal
s a welcome reminder of the fallacy of the concern with low
P in administering carvedilol. As the authors point out,
ow BP is often cited as a reason for not administering a
eta-blocker in HF despite the impressive data supporting
ts long-term efficacy. The vasodilator action of carvedilol
elated to its alpha-blocking effects should in fact be
eneficial in such patients, just as it was in our early patient
xperience. As nicely documented by Rouleau et al. (7), low
ntrance BP in the Carvedilol Prospective Randomized
umulative Survival (COPERNICUS) trial was a powerful
ortality risk factor and identified patients in particular
eed for aggressive therapy.
It is important to reiterate an often-disregarded principle
n the management of HF. Symptoms of decompensated
F are a consequence of long-term structural remodeling of
he heart complicated by short-term and often reversible
ysfunction related to heightened impedance and a contrac-
ile disorder. Lowering the impedance or increasing the
ontractility can reverse the functional disorder (8) but not
ecessarily the long-term structural disorder. Beta-blockers
eal with the structural disorder (9). Vasodilators correct the
unctional disorder, and some vasodilators (e.g., nitrates,
ngiotensin-converting enzyme inhibitors, angiotensin re-
eptor blockers) also favorably affect the structural disorder
10–12). Alpha blockers are not among these (10), so the
lpha-blocker activity of carvedilol may be important in
estoring LV function in these hypotensive patients with
F, but it probably does not contribute to the long-term
tructural benefit of the beta-blocking activity of carvedilol.The message of the Rouleau et al. study (7) should be
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April 21, 2004:1430–1 Editorial Commentlear. Hypotension in severe HF is grave and helps physi-
ians identify patients who are in need of aggressive therapy
o improve emptying of the LV and, long-term, to correct
ts structural remodeling. Vasodilator therapy can usually be
olerated by such patients and indeed perhaps should be
andated. Low BP should not preclude a trial with such
rugs, and a fall in BP not accompanied by hypotensive
igns or symptoms should not necessarily lead to a discon-
inuation of the therapy.
Carvedilol is dual therapy: Its vasodilator effect supports
V function, whereas its beta-blocking effect exerts long-
erm benefits. One could alternatively use a vasodilator, such
s a nitrate (often combined with hydralazine to preserve the
enerated nitric oxide) (13) and a purer beta-blocker to
btain the same effect. The latter combination would have
he benefit of separate titration to optimal doses of the
asodilator and beta-blocker and would also have the benefit
f additional antiremodeling properties of the nitrate (14).
n the meantime, however, the experience with carvedilol in
OPERNICUS suggests that it is safe and effective in this
atient population.
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